Treatment Sequence Studied for Advanced BRAF - Mutant Melanoma

Two - year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news